India–UK trade agreement comes into effect: What it means for MedTech

India–UK Comprehensive Economic and Trade Agreement (CETA) comes into effect on July 15, 2026. It marks a new phase in bilateral trade with wide-ranging implications for the healthcare and medical technology sector.

The subtext of the agreement is lower MedTech tariffs, smoother regulatory pathways, and a more connected innovation ecosystem spanning hospitals and diagnostics in both countries.

Tariffs on MedTech: From double-digits to single-digits
India has committed to reducing customs duties on selected UK-origin medical devices, cutting typical tariffs from the 7.5 to15 percent range down to roughly 3 percent over a phased schedule.

Industry associations such as the Medical Technology Association of India (MTaI) describe this as a `landmark’ shift that will immediately improve affordability of high-end equipment and consumables in the Indian market.

Key elements for MedTech trade include:

• Tariff reductions on UK medical devices such as imaging systems, diagnostics, and surgical instruments, implemented in tranches from July 15.
• Elimination or near-elimination of tariffs on the vast majority of Indian medical device exports to the UK, with duty-free access covering almost all product lines.
• The ability for importers and exporters to choose between preferential CETA rates and existing MFN duties where those remain more favourable, allowing strategic tariff planning.

For UK manufacturers, lower Indian tariffs make advanced technologies more price-competitive for both corporate hospital chains and tier-II/III providers that have traditionally been priced out of the latest equipment. For Indian MedTech exporters, zero-duty access strengthens margins and enables more aggressive pricing in the UK’s sizable medical device market.

Indian MedTech: Exports poised to scale up
India’s medical device industry, which is eyeing to reach USD 30 billion or more by 2030, has identified the UK as a priority growth market. Under the new trade regime, nearly 99 percent of Indian product types will enter the UK tariff-free, covering almost the entire MedTech export basket.

Policy dialogues and industry consultations suggest ambitious export goals:

• Indian MedTech exporters aim to more than double or even triple shipments to the UK by 2030, building on current volumes in the Rs 1,100 crore range.
• Generic, value-driven devices such as syringes, catheters, basic monitoring systems, and surgical instruments are expected to gain rapid share due to their cost advantage and now formalised tariff-free status.
• Companies see opportunities to grow in higher-value segments, including orthopaedic implants, cardiovascular devices, and advanced diagnostics, where joint R&D and technology transfer can raise product sophistication.

Executives from leading Indian firms indicate that the agreement will accelerate competitiveness and support investments in UK-facing product lines, contract manufacturing, and local distribution partnerships.

Regulatory cooperation and market access: Beyond tariffs
Crucially, the agreement goes further than tariff relief, laying groundwork for closer regulatory and standards cooperation in health and MedTech. Stakeholders on both sides expect gains from:

Greater alignment with international medical device standards and more predictable approval pathways in the UK for Indian-origin products.

Discussions around mutual recognition or streamlined handling of Indian certifications (such as CDSCO and ICMED), reducing duplication of testing and documentation

Simplified customs procedures, self-certification of origin, and commitments to faster clearance of compliant consignments, which can cut lead times for critical medical supplies.

For Indian manufacturers, smoother regulatory routes address one of the biggest non-tariff barriers to entering the UK: high compliance costs and lengthy review timelines. For UK companies, closer engagement with Indian regulators supports safer, faster introduction of novel technologies in a fast-growing healthcare market.

Digital health, SaMD, and hospital procurement
The India–UK deal also includes provisions affecting digital trade, intellectual property, and services, which are directly relevant to software-driven medical technologies and health IT. Analysts point to several emerging opportunities:

Expansion of Software as a Medical Device (SaMD), AI-enabled clinical decision tools, and remote monitoring platforms backed by clearer rules on data flows and IP protection.

Joint development of telehealth, virtual care, and remote diagnostics solutions, leveraging India’s IT and health-tech talent with the UK’s demand for cost-effective digital care models.

Participation by MedTech companies in government procurement and healthcare infrastructure programmes in both countries, supported by more transparent rules under the new framework.

For Indian hospitals and diagnostic chains, lower tariffs on hardware combined with greater availability of UK-origin software and connectivity solutions can accelerate the shift to integrated, data-driven care.

Risks and watch-points for industry
While industry bodies have largely welcomed the agreement, MedTech players also flag areas that need careful monitoring. Concerns include:

• The possibility of third-country medical products being routed through the UK to exploit tariff concessions, which could complicate quality oversight and market fairness.
• Uncertainty around how far regulatory streamlining will go in practice, and whether mutual recognition arrangements will truly reduce compliance burdens.
• The ongoing balance between stronger IP protection and the need to preserve access to affordable medicines and technologies, especially in low-resource settings.

Indian industry associations have called for robust monitoring of imports, clear guidance on rules of origin, and a proactive stance from regulators to prevent misuse of the agreement while preserving genuine trade and collaboration.

What it means for Indian stakeholders
For Indian hospitals, diagnostic chains, and device manufacturers, the India–UK trade agreement opens a multi-layered set of opportunities across price, technology, and partnerships.

• Hospital and diagnostic buyers can expect gradual price relief on selected UK-origin devices and consumables, particularly in imaging, critical care, and high-end diagnostics, improving access to advanced technologies beyond metro tertiary centres.
• Indian manufacturers gain clearer, tariff-free access to the UK market, supporting export-led scale-up and justifying investments in international-quality design, manufacturing, and quality systems.
• Both sides can use the agreement as a platform for deeper collaboration in R&D, digital health, and skill development, reinforcing India’s ambition to become a top-five global MedTech manufacturing hub by 2030.

For decision-makers in India’s healthcare ecosystem, the strategic question now is less about whether tariffs will fall and more about how quickly they can realign procurement, manufacturing, and partnership strategies to capture the MedTech upside of this new trade architecture.

India–UK MedTech tariffs: indicative pre and post FTA levels

These ranges reflect how the agreement:
Brings many UK origin devices entering India down from high single or low double digit duties into a roughly 3 percent band.

Eliminates or nearly eliminates tariffs on the vast majority of Indian MedTech exports to the UK, treating them similarly to other priority industrial sectors covered under the 90–99 percent liberalisation of tariff lines.
MB Bureau